Trade AbbVie ^ABBV

Abbvie's Crohn's Disease Drug Skyrizi Shows More Positive Results | Morningstar

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease | Morningstar

AbbVie Inc. $ABBV Stock Bought by Sivik Global Healthcare LLC - Markets Daily

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® in Patients With Moderately to Severely Active Crohn's Disease | INN

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income - 24/7 Wall St.

Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests

AbbVie (NYSE:ABBV) Stock Keeps Outperform Rating at Royal Bank Of Canada

Royal Bank Of Canada Reaffirms "Outperform" Rating for AbbVie (NYSE:ABBV)

7,000 AbbVie Inc. $ABBV Shares Purchased by Sivik Global Healthcare LLC - Stock Observer

Investment Analysts' Updated EPS Estimates for October 13th (ABBV, ACAD, ALNT, BCE, CTNM, DPZ, EFXT, GEMI, GEV, GNC) - Stock Observer

4,692 AbbVie Inc. $ABBV Shares Bought by Sax Wealth Advisors LLC - Daily Political

AbbVie (NYSE:ABBV) Stock Rating Reaffirmed as Outperform by Royal Bank Of Canada - Daily Political

AbbVie's (ABBV) "Outperform" Rating Reiterated at Royal Bank Of Canada - Daily Political

AbbVie (NYSE:ABBV) Given "Outperform" Rating at Royal Bank Of Canada - Daily Political

AbbVie (NYSE:ABBV) Reaches New 52-Week High - Here's Why

AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline Wins

Biotech Stocks To Watch Today - October 11th - Daily Political

AbbVie (NYSE:ABBV) Stock Jumps 1.6% - Should You Buy?

Prediction: AbbVie's Next Billion-Dollar Opportunity Is Taking Shape

AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026

AbbVie (NYSE:ABBV) Stock Rating Reaffirmed as "Buy" by Guggenheim - Stock Observer

AbbVie (NYSE:ABBV) Earns Buy Rating from Guggenheim - Stock Observer

AbbVie (NYSE:ABBV) Given "Buy" Rating at Guggenheim - Stock Observer

AbbVie's (ABBV) Buy Rating Reaffirmed at Guggenheim - Stock Observer

Guggenheim Reaffirms "Buy" Rating for AbbVie (NYSE:ABBV) - Stock Observer

AbbVie (NYSE:ABBV) Stock Keeps Buy Rating at Guggenheim - Stock Observer

NSCLC Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Merck | ABNewswire

AbbVie announces presentation of 22 scientific abstracts from IBD portfolio

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease | Morningstar

5 Dividend Stocks for Retirees Who Want More Than Just a Big Yield

Promising Pharmaceutical Stocks To Follow Now - October 11th - Daily Political

AbbVie (NYSE:ABBV) Price Target Raised to $300.00 - Stock Observer

Top Biotech Stocks To Watch Now - October 10th - Markets Daily

American Hospital Association Sues Over 340B Pilot Program Invol

Oak Grove Capital LLC Buys 17,000 Shares of AbbVie Inc. $ABBV

AbbVie Inc. $ABBV Shares Acquired by Wedmont Private Capital

AbbVie Inc. $ABBV Shares Sold by Davidson Trust Co.

Capital Planning LLC Sells 7,500 Shares of AbbVie Inc. $ABBV

Sound Income Strategies LLC Buys 2,040 Shares of AbbVie Inc. $ABBV - Daily Political

Mirador Capital Partners LP Buys 2,072 Shares of AbbVie Inc. $ABBV - Daily Political

AbbVie (NYSE:ABBV) Stock Price Up 1.4% on Analyst Upgrade

Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

Treasury Bills or Dividend Stocks? The Retirement Income Math May Surprise You

AbbVie (NYSE:ABBV) Shares Climb 1.4% After Analyst Upgrade - Daily Political

Equities Research Analysts' Updated EPS Estimates for October 9th (ABBV, ALAB, ANGO, APA, AVO, CBOE, COST, CRE, CTSH, CVNA) - Stock Observer

AbbVie's (ABBV) Buy Rating Reiterated at Guggenheim

AbbVie (ABBV) Outgrew Humira's Collapse. Is its Forward P/E Fair for What Comes Next?

Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks

AbbVie Inc. $ABBV Shares Purchased by Mn Services Vermogensbeheer B.V.

GAMMA Investing LLC Purchases 7,058 Shares of AbbVie Inc. $ABBV

AbbVie Inc. $ABBV Stock Sold by Bell Asset Management Ltd

AbbVie Inc. $ABBV Position Increased by Farther Finance Advisors LLC - Zolmax

14,020 AbbVie Inc. $ABBV Shares Acquired by Sapient Capital LLC

AbbVie Inc. $ABBV Shares Bought by Meadowbrook Wealth Management LLC - Markets Daily

AbbVie Inc. $ABBV Shares Acquired by Meadowbrook Wealth Management LLC - Zolmax

AbbVie Inc. $ABBV Stock Acquired by Farther Finance Advisors LLC

AbbVie (NYSE:ABBV) Stock Gets Price Target Bump from JPMorgan Chase & Co.

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock - Zolmax

AbbVie Inc. $ABBV Stock Sold by Hamlin Capital Management LLC

AbbVie Inc. $ABBV Stock Acquired by Artemis Investment Management LLP

AbbVie Inc. $ABBV Stock Position Increased by Toth Financial Advisory Corp - Stock Observer

AbbVie (NYSE:ABBV) Price Target Raised to $290.00

Biotech Stocks At 52-Week Highs - ABBV On FDA Designations, HSTM, OGN

8,817 AbbVie Inc. $ABBV Shares Bought by Congress Asset Management Co.

AbbVie (NYSE:ABBV) Issues Q3 2026 Earnings Guidance - Stock Observer

AbbVie (NYSE:ABBV) Stock Price Expected to Rise, Scotiabank Analyst Says

Biotech Stocks To Keep An Eye On - October 6th - Markets Daily

3 'Strong Buy' Dividend Aristocrat Stocks on Analysts' Watch List

Johnson & Johnson (JNJ) Is Becoming a Growth Stock. Does AbbVie (ABBV) Make JNJ Look Expensive?

AbbVie (NYSE:ABBV) Stock Price Up 1.8% Following Analyst Upgrade

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

2,008 AbbVie Inc. $ABBV Shares Sold by Canandaigua National Bank & Trust Co. - Stock Observer

5,659 AbbVie Inc. $ABBV Shares Sold by MRA Advisory Group

American National Bank & Trust Reduces Stake in AbbVie Inc. $ABBV

AbbVie's Temab-A Earns FDA Breakthrough Therapy Designations In CRC, NSCLC;Stock Up

AbbVie's Telisotuzumab Adizutecan Secures Dual FDA Breakthrough Therapy Designations

AbbVie (NYSE:ABBV) Hits New 12-Month High on Analyst Upgrade - Stock Observer

Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?

AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%

AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?

AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%

Forget Bonds: How Retirees Collect $6,650 a Month From Dividends Alone

AbbVie Inc. $ABBV Stock Sold by Hall Laurie J Trustee - Daily Political

Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss

Abbvie-Genmab Epkinly data signal first-line filing for DLBCL

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms

Scotiabank Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock

$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely

AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug | Morningstar